JPWO2019140266A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140266A5 JPWO2019140266A5 JP2020538819A JP2020538819A JPWO2019140266A5 JP WO2019140266 A5 JPWO2019140266 A5 JP WO2019140266A5 JP 2020538819 A JP2020538819 A JP 2020538819A JP 2020538819 A JP2020538819 A JP 2020538819A JP WO2019140266 A5 JPWO2019140266 A5 JP WO2019140266A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- conjugate
- composition
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US62/711,423 | 2018-07-27 | ||
| US62/711,421 | 2018-07-27 | ||
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US62/716,796 | 2018-08-09 | ||
| US62/716,788 | 2018-08-09 | ||
| PCT/US2019/013306 WO2019140266A1 (en) | 2018-01-12 | 2019-01-11 | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510701A JP2021510701A (ja) | 2021-04-30 |
| JP2021510701A5 JP2021510701A5 (https=) | 2022-03-16 |
| JPWO2019140266A5 true JPWO2019140266A5 (https=) | 2022-03-16 |
Family
ID=67218383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20200360545A1 (https=) |
| EP (2) | EP3737383A4 (https=) |
| JP (3) | JP2021510701A (https=) |
| KR (2) | KR20200109345A (https=) |
| CN (2) | CN111587126A (https=) |
| AU (2) | AU2019208024A1 (https=) |
| CA (2) | CA3087628A1 (https=) |
| MX (3) | MX2020007306A (https=) |
| RU (1) | RU2020126774A (https=) |
| WO (2) | WO2019140266A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| CN114615978A (zh) * | 2019-08-28 | 2022-06-10 | 普罗林科斯有限责任公司 | Dna损伤响应的偶联抑制剂 |
| CN119213060A (zh) * | 2022-04-14 | 2024-12-27 | 国立研究开发法人量子科学技术研究开发机构 | 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒 |
| WO2024030998A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
| WO2024031005A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998030575A1 (en) | 1997-01-08 | 1998-07-16 | Proligo Llc | Bioconjugation of macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20040176270A1 (en) | 2002-07-12 | 2004-09-09 | Biomarin Pharmaceutical Inc. | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| EP1580216B1 (en) | 2002-10-31 | 2014-05-14 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| ES2629696T3 (es) | 2003-09-17 | 2017-08-14 | Nektar Therapeutics | Profármacos poliméricos multibrazo |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| MX2009002855A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| WO2009141826A2 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| CA2738807A1 (en) | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| JP2012509469A (ja) | 2008-11-18 | 2012-04-19 | バクスター・インターナショナル・インコーポレイテッド | ポリエチレングリコールサンプルの多分散度および／または分子量分布を決定する方法 |
| WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| US8703907B2 (en) | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| TW201215412A (en) | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| IN2014MN01819A (https=) * | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| TWI486341B (zh) * | 2012-05-18 | 2015-06-01 | 高雄醫學大學 | 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法 |
| US9863949B2 (en) * | 2013-05-31 | 2018-01-09 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) * | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| WO2015183876A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| CA2957721C (en) * | 2014-08-13 | 2021-04-13 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| WO2016028636A1 (en) | 2014-08-16 | 2016-02-25 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| PL3560924T3 (pl) | 2015-04-02 | 2021-10-11 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| CA2980462C (en) * | 2015-04-07 | 2023-08-01 | The Curators Of The University Of Missouri | Nanoparticle immunoconjugates |
| WO2016176462A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| EP3337467B1 (en) * | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| US11154538B2 (en) | 2016-02-29 | 2021-10-26 | Synta Pharmaceuticals Corporation | Combination therapy for treatment of ovarian cancer |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| JP7379795B2 (ja) | 2016-04-27 | 2023-11-15 | イミューノメディクス、インコーポレイテッド | チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果 |
| CN109069666B (zh) | 2016-04-29 | 2023-04-04 | 纪念斯隆凯特琳癌症中心 | 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法 |
| CN106084005B (zh) * | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en not_active Ceased
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en not_active Abandoned
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en not_active Withdrawn
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en not_active Withdrawn
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en not_active Ceased
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Ceased
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en not_active Abandoned
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Ceased
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en not_active Abandoned
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en not_active Abandoned
- 2023-10-31 JP JP2023186470A patent/JP7703001B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510701A5 (https=) | ||
| Sharma et al. | Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery | |
| Cabral et al. | Supramolecular nanodevices: from design validation to theranostic nanomedicine | |
| Guo et al. | Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles | |
| Xiao et al. | Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging | |
| Nabi et al. | Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer | |
| Faure et al. | Control of the in vivo biodistribution of hybrid nanoparticles with different poly (ethylene glycol) coatings | |
| Wu et al. | Oligo (ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration | |
| Zhang et al. | Shape effects of cylindrical versus spherical unimolecular polymer nanomaterials on in vitro and in vivo behaviors | |
| Pant et al. | Radiolabelled polymeric materials for imaging and treatment of cancer: quo vadis? | |
| Voulgari et al. | Synthesis, characterization and in vivo evaluation of a magnetic cisplatin delivery nanosystem based on PMAA-graft-PEG copolymers | |
| Lim et al. | The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers | |
| KR101384991B1 (ko) | 온도 및 피에이치 민감성 하이드로젤의 인터벤셔널 인젝션에 기반한 간암치료용 약물전달체 | |
| Zhao et al. | Polyethylenimine-based theranostic nanoplatform for glioma-targeting single-photon emission computed tomography imaging and anticancer drug delivery | |
| RU2020126774A (ru) | Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения | |
| Hue et al. | Distribution and accumulation of Cy5. 5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice | |
| Goos et al. | Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue | |
| Misra et al. | Smart nanotheranostic hydrogels for on-demand cancer management | |
| Guo et al. | A nitroxides-based macromolecular MRI contrast agent with an extraordinary longitudinal relaxivity for tumor imaging via clinical T1WI SE sequence | |
| Zu et al. | Development of an aptamer-conjugated polyrotaxane-based biodegradable magnetic resonance contrast agent for tumor-targeted imaging | |
| Ali et al. | Advances in nanoparticles as anticancer drug delivery vector: need of this century | |
| Miura et al. | Polymeric micelle platform for multimodal tomographic imaging to detect scirrhous gastric cancer | |
| US8961949B2 (en) | Polymer-metal complex composite having MRI contrast ability and MRI contrasting and/or antitumor composition using the same | |
| Makino et al. | Solid Tumor‐Targeting Theranostic Polymer Nanoparticle in Nuclear Medicinal Fields | |
| JPWO2019140266A5 (https=) |